Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

Partner | Cancer Centers | <b>Yale Cancer Center</b>

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.